Potent 2'-amino-2'-deoxypyrimidine RNA inhibitors of basic fibroblast growth factor.

Screening of random oligonucleotide libraries with SELEX [systematic evolution of ligands by exponential enrichment; Tuerk, C., & Gold, L. (1990) Science 249, 505-510] has emerged as a powerful method for identifying high-affinity nucleic acid ligands for a wide range of molecular targets. Nuclease sensitivity of unmodified RNA and DNA, however, imposes considerable restrictions on their use as therapeutics or diagnostics. Modified RNA in which pyrimidine 2'-hydroxy groups have been substituted with 2'-amino groups (2'-aminopyrimidine RNA) is known to be substantially more resistant to serum nucleases. We report here on the use of SELEX to identify high-affinity 2'-aminopyrimidine RNA ligands to a potent angiogenic factor, basic fibroblast growth factor (bFGF). High-affinity ligands with the same consensus primary structure have been isolated from two independent libraries of approximately 6 x 10(14) molecules containing 30 or 50 randomized positions. Compared to unmodified RNA with the same sequence, 2'-aminopyrimidine ligands are at least 1000-fold more stable in 90% human serum. The sequence information required for high-affinity binding to bFGF is contained within 24-26 nucleotides. The minimal ligand m21A (5'-GGUGUGUGGAAGACAGCGGGUGGUUC-3'; G = guanosine, A = adenosine, C = 2'-amino-2'-deoxycytidine, U = 2'-amino-2'-deoxyuridine, and C = 2'-amino-2'-deoxycytidine or deoxycytidine) binds to bFGF with an apparent dissociation constant (Kd) of 3.5 +/- 0.3) x 10(-10) M at 37 degrees C in phosphate-buffered saline (pH 7.4). Disassociation of m21A from bFGF is adequately described with a first-order rate constant of (1.96 +/- 0.08) x 10(-3) s-1 (t1/2 = 5.9 min). The calculated value for the association rate constant (kon = k(off)/Kd) was 5.6 x 10(6) M-1 s-1. Highly specific binding of m21A to bFGF was observed: binding to denatured bFGF, five proteins from the FGF family (acidic FGF, FGF-4, FGF-5, FGF-6, and FGF-7), and four other heparin binding proteins is substantially weaker under the same conditions with KdbFGF/Kdprotein values ranging from (4.1 +/- 1.4) x 10(-2) to > 10(-6). Heparin but not chondroitin sulfate competed for binding of m21A to bFGF. In cell culture, m21A inhibited [125I]bFGF binding to both low-affinity sites (ED50 approximately 1 nM) and high-affinity sites (ED50 approximately 3 nM) on CHO cells expressing transfected FGF receptor-1.(ABSTRACT TRUNCATED AT 400 WORDS)

[1]  L. Gold,et al.  Oligonucleotides as Research, Diagnostic, and Therapeutic Agents(*) , 1995, The Journal of Biological Chemistry.

[2]  H. Engelhard,et al.  Suramin, an anticancer and angiosuppressive agent, inhibits endothelial cell binding of basic fibroblast growth factor, migration, proliferation, and induction of urokinase-type plasminogen activator. , 1994, Cancer research.

[3]  M. Presta,et al.  Purification of a factor from human placenta that stimulates capillary endothelial cell protease production, DNA synthesis, and migration. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[4]  Y. Lin,et al.  Modified RNA sequence pools for in vitro selection. , 1994, Nucleic acids research.

[5]  N. Quarto,et al.  Transformation of NIH 3T3 cells with basic fibroblast growth factor or the hst/K-fgf oncogene causes downregulation of the fibroblast growth factor receptor: reversal of morphological transformation and restoration of receptor number by suramin , 1989, The Journal of cell biology.

[6]  J. Taylor An Introduction to Error Analysis , 1982 .

[7]  C. Stein,et al.  Phosphorothioate Oligodeoxynucleotides Bind to Basic Fibroblast Growth Factor, Inhibit Its Binding to Cell Surface Receptors, and Remove It from Low Affinity Binding Sites on Extracellular Matrix (*) , 1995, The Journal of Biological Chemistry.

[8]  T. Fan,et al.  A structure-activity analysis of antagonism of the growth factor and angiogenic activity of basic fibroblast growth factor by suramin and related polyanions. , 1994, British Journal of Cancer.

[9]  F. Eckstein,et al.  Kinetic characterization of ribonuclease-resistant 2'-modified hammerhead ribozymes. , 1991, Science.

[10]  R. Sasada,et al.  Suppression of solid tumor growth by immunoneutralizing monoclonal antibody against human basic fibroblast growth factor. , 1991, Cancer research.

[11]  N. Janjić,et al.  Inhibition of receptor binding by high-affinity RNA ligands to vascular endothelial growth factor. , 1994, Biochemistry.

[12]  Y. Osada,et al.  Inhibitory effects of a bacteria‐derived sulfated polysaccharide against basic fibroblast growth factor‐induced endothelial cell growth and chemotaxis , 1993, Journal of cellular physiology.

[13]  M. Presta,et al.  Purification from a human hepatoma cell line of a basic fibroblast growth factor-like molecule that stimulates capillary endothelial cell plasminogen activator production, DNA synthesis, and migration , 1986, Molecular and cellular biology.

[14]  J. Lear,et al.  Multivalent ligand-receptor binding interactions in the fibroblast growth factor system produce a cooperative growth factor and heparin mechanism for receptor dimerization. , 1994, Biochemistry.

[15]  P. Black,et al.  Microvessel count and cerebrospinal fluid basic fibroblast growth factor in children with brain tumours , 1994, The Lancet.

[16]  K. Matsumoto,et al.  Cloning and characterization of an androgen-induced growth factor essential for the androgen-dependent growth of mouse mammary carcinoma cells. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[17]  J. Fiddes,et al.  Human basic fibroblast growth factor: nucleotide sequence and genomic organization. , 1986, The EMBO journal.

[18]  M. Rusnati,et al.  Internalization of basic fibroblast growth factor (bFGF) in cultured endothelial cells: Role of the low affinity heparin‐like bFGF receptors , 1993, Journal of cellular physiology.

[19]  J. Richie,et al.  Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers. , 1994, Journal of the National Cancer Institute.

[20]  D. Williams,et al.  2'-Fluoro- and 2'-amino-2'-deoxynucleoside 5'-triphosphates as substrates for T7 RNA polymerase. , 1992, Biochemistry.

[21]  Jeffrey D. Esko,et al.  Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor , 1991, Cell.

[22]  J. Szostak,et al.  In vitro selection of RNA molecules that bind specific ligands , 1990, Nature.

[23]  M. Klagsbrun,et al.  Heparin affinity of anionic and cationic capillary endothelial cell growth factors: analysis of hypothalamus-derived growth factors and fibroblast growth factors. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[24]  D. Moscatelli,et al.  High and low affinity binding sites for basic fibroblast growth factor on cultured cells: Absence of a role for low affinity binding in the stimulation of plasminogen activator production by bovine capillary endothelial cells , 1987, Journal of cellular physiology.

[25]  F. Eckstein,et al.  Polynucleotides containing 2'-amino-2'-deoxyribose and 2'-azido-2'-deoxyribose. , 1973, Biochemistry.

[26]  V. Baldin,et al.  Translocation of bFGF to the nucleus is G1 phase cell cycle specific in bovine aortic endothelial cells. , 1990, The EMBO journal.

[27]  L. Gold,et al.  Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. , 1990, Science.

[28]  L. Ellis,et al.  The implications of angiogenesis for the biology and therapy of cancer metastasis , 1994, Cell.

[29]  D. Rifkin,et al.  Inhibition of endothelial cell movement by pericytes and smooth muscle cells: activation of a latent transforming growth factor-beta 1-like molecule by plasmin during co-culture , 1989, The Journal of cell biology.

[30]  N. Quarto,et al.  Fibroblast growth factor-2 (FGF-2) in the nucleus: translocation process and targets. , 1994, Biochemical pharmacology.

[31]  A. Pardi,et al.  High-resolution molecular discrimination by RNA. , 1994, Science.

[32]  J. Feigon,et al.  Thrombin-binding DNA aptamer forms a unimolecular quadruplex structure in solution. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[33]  Lars Holmgren,et al.  Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinoma , 1994, Cell.

[34]  M Yarus,et al.  Diversity of oligonucleotide functions. , 1995, Annual review of biochemistry.

[35]  D. Rifkin,et al.  Heparin increases the affinity of basic fibroblast growth factor for its receptor but is not required for binding. , 1994, The Journal of biological chemistry.

[36]  J. G. Moffatt,et al.  Synthesis of some pyrimidine 2'-amino-2'-deoxynucleosides. , 1971, The Journal of organic chemistry.

[37]  J. Takahashi,et al.  Inhibition of cell growth and tumorigenesis of human glioblastoma cells by a neutralizing antibody against human basic fibroblast growth factor , 1991, FEBS letters.

[38]  T. D. Schneider,et al.  Information content of binding sites on nucleotide sequences. , 1986, Journal of molecular biology.

[39]  K. Jankowski,et al.  Nucleoside conformation is determined by the electronegativity of the sugar substituent. , 1980, Nucleic acids research.

[40]  L. Cousens,et al.  Preparation of affinity-fractionated, heparin-derived oligosaccharides and their effects on selected biological activities mediated by basic fibroblast growth factor. , 1993, The Journal of biological chemistry.

[41]  M. Benezra,et al.  Reversal of basic fibroblast growth factor-mediated autocrine cell transformation by aromatic anionic compounds. , 1992, Cancer research.

[42]  J. Fiddes,et al.  Nucleotide sequence of a bovine clone encoding the angiogenic protein, basic fibroblast growth factor. , 1986, Science.

[43]  O. Uhlenbeck,et al.  Oligoribonucleotide synthesis using T7 RNA polymerase and synthetic DNA templates. , 1987, Nucleic acids research.

[44]  J. Latham,et al.  The application of a modified nucleotide in aptamer selection: novel thrombin aptamers containing 5-(1-pentynyl)-2'-deoxyuridine. , 1994, Nucleic acids research.

[45]  F. Eckstein,et al.  Facile synthesis of 2'-amino-2'-deoxyribofuranosylpurines , 1979 .

[46]  J. Biernat,et al.  Polymer support oligonucleotide synthesis XVIII: use of beta-cyanoethyl-N,N-dialkylamino-/N-morpholino phosphoramidite of deoxynucleosides for the synthesis of DNA fragments simplifying deprotection and isolation of the final product. , 1984, Nucleic acids research.

[47]  D. Moscatelli,et al.  The FGF family of growth factors and oncogenes. , 1992, Advances in cancer research.

[48]  N. Janjić,et al.  High-affinity RNA ligands to basic fibroblast growth factor inhibit receptor binding. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[49]  S. Scaringe,et al.  Chemical synthesis of biologically active oligoribonucleotides using beta-cyanoethyl protected ribonucleoside phosphoramidites. , 1990, Nucleic acids research.

[50]  B. Olwin,et al.  Requirement of heparan sulfate for bFGF-mediated fibroblast growth and myoblast differentiation , 1991, Science.

[51]  N. S. Mcnutt,et al.  Differential expression of basic fibroblast growth factor (bFGF) in melanocytic lesions demonstrated by in situ hybridization. Implications for tumor progression. , 1994, The American journal of pathology.

[52]  J. Folkman,et al.  Anti‐Angiogenesis: New Concept for Therapy of Solid Tumors , 1972, Annals of surgery.

[53]  D. Moscatelli,et al.  Basic fibroblast growth factor (bFGF) dissociates rapidly from heparan sulfates but slowly from receptors. Implications for mechanisms of bFGF release from pericellular matrix. , 1992, The Journal of biological chemistry.

[54]  D. Rifkin,et al.  In vitro angiogenesis on the human amniotic membrane: requirement for basic fibroblast growth factor-induced proteinases , 1989, The Journal of cell biology.

[55]  L. Gold,et al.  Selection of high affinity RNA ligands to the bacteriophage R17 coat protein. , 1992, Journal of molecular biology.

[56]  D. Gospodarowicz,et al.  The identification and partial characterization of the fibroblast growth factor receptor of baby hamster kidney cells. , 1985, The Journal of biological chemistry.

[57]  J. Massagué,et al.  Cellular receptors for type beta transforming growth factor. Ligand binding and affinity labeling in human and rodent cell lines. , 1985, The Journal of biological chemistry.

[58]  Fritz Eckstein,et al.  Oligonucleotide duplexes containing 2'-amino-2'-deoxycytidines: thermal stability and chemical reactivity [published erratum appears in Nucleic Acids Res 1994 Feb 25;22(4): 701] , 1994, Nucleic Acids Res..

[59]  A. Rapraeger,et al.  Heparan sulfate proteoglycan and FGF receptor target basic FGF to different intracellular destinations. , 1993, Journal of cell science.

[60]  T. Kurokawa,et al.  Molecular cloning of a novel cytokine cDNA encoding the ninth member of the fibroblast growth factor family, which has a unique secretion property , 1993, Molecular and cellular biology.

[61]  T. Maione,et al.  Development of angiogenesis inhibitors for clinical applications. , 1990, Trends in pharmacological sciences.

[62]  L. Kan,et al.  Syntheses and Interactions of Oligodeoxyribonucleotides Containing 2′-Amino-2′-Deoxyuridine , 1993 .